The patent has been granted The patent has been granted, Grant of patent is intended, Examination is in progress, Request for examination was made, The application has been published, The international publication has been made EP Register Verified

METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES

Publication No. EP3752180

•

App No. EP19754909

•

Filed by Merck Sharp & Dohme LLC

•

Filed on 2019-02-08

•

Issued/Published on 2026-07-22

Official EPO Register

Publication No. EP3752180 A2

Application No. EP19754909 Filed: 2019-02-08

Grant Date 2026-07-22 Mention of grant

Active Oppositions 3 Active EPO Oppositions

Patent Abstract / Summary

Patent abstract is being processed or was not provided in English by the publishing office.

IPC Classifications

C07K16/28, A61K39/00, A61K39/395, A61P35/00 A61K39/00, A61K39/395, A61P35/00 A61K39/00

Priority Claims

US 201862630038P Date: 2018-02-13

US 201862732828P Date: 2018-09-18

Designated Contracting States (38 EPC States)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Parties & Representation

Applicants

Merck Sharp & Dohme LLC

126 East Lincoln Avenue, Rahway, New Jersey 07065

Merck Sharp & Dohme Corp.

126 East Lincoln Road, Rahway, New Jersey 07065-0907

Inventors (3)

LALA, Mallika

126 East Lincoln Avenue, Rahway, New Jersey 07065-0907

JAIN, Lokesh

126 East Lincoln Avenue, Rahway, New Jersey 07065-0907

LI, Mengyao

42 Forest Drive, Apt. B, Springfield, New Jersey 07084

Representatives / Agents

Carpmaels & Ransford LLP

One Southampton Row, London WC1B 5HA

Böhles, Elena

Merck Sharp & Dohme Limited, Hertford Road

Ter Meer und Partner mbB

Nymphenburger Str. 4, Zugang Dachauer Str. 63

Wichmann, Hendrik

Wuesthoff & Wuesthoff, Patentanwälte und Rechtsanwalt PartG mbB

Ter Meer Steinmeister & Partner

Patentanwälte mbB, Nymphenburger Straße 4

Key Procedural Dates

Request-For-Examination 2021-03-10

First-Examination-Report-Despatched 2023-08-04

Patent Oppositions

Official opposition proceedings filed against European Patent EP3752180 under EPC Article 99.

3 ACTIVE OPPONENTS

Opponent Company

Abbott Production Operations AG

Hegenheimermattweg 127, CH

Representative

Ter Meer und Partner mbB

Filing Date

2026-07-22

Opposition in Progress

Opponent Company

Wuesthoff & Wuesthoff Patentanwälte und Rechtsanwalt PartG mbB

Schweigerstr. 2, DE

Representative

Wichmann, Hendrik

Filing Date

2026-08-17

Opposition in Progress

Opponent Company

Abbott Production Operations AG

Hegenheimermattweg 127, CH

Representative

Ter Meer Steinmeister & Partner

Filing Date

2026-07-22

Opposition in Progress

Legal Status & Event History

Official European Patent Office legal and procedural status changes recorded for this file.

42 Events Recorded

Date	Code	Event Description	Auth
2020-12-23	AX	REQUEST FOR EXTENSION OF THE EUROPEAN PATENT	EP
2020-12-23	AK	DESIGNATED CONTRACTING STATES	EP
2021-03-19	TPAC	OBSERVATIONS FILED BY THIRD PARTIES	EP
2021-04-14	RAV	REQUESTED VALIDATION STATE OF THE EUROPEAN PATENT: FEE PAID	EP
2021-04-14	17P	REQUEST FOR EXAMINATION FILED	EP
2021-04-14	RBV	DESIGNATED CONTRACTING STATES (CORRECTED)	EP
2021-04-14	RAX	REQUESTED EXTENSION STATES OF THE EUROPEAN PATENT HAVE CHANGED	EP
2021-04-30	REG	REFERENCE TO A NATIONAL CODE	EP
2020-11-20	PUAI	PUBLIC REFERENCE MADE UNDER ARTICLE 153(3) EPC TO A PUBLISHED INTERNATIONAL APPLICATION THAT HAS ENTERED THE EUROPEAN PHASE	EP
2021-03-12	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2020-11-20	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2019-08-24	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2021-08-18	RAV	REQUESTED VALIDATION STATE OF THE EUROPEAN PATENT: FEE PAID	EP
2021-12-15	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2021-12-15	A4	SUPPLEMENTARY SEARCH REPORT DRAWN UP AND DESPATCHED	EP
2022-10-19	RAP1	PARTY DATA CHANGED (APPLICANT DATA CHANGED OR RIGHTS OF AN APPLICATION TRANSFERRED)	EP
2023-08-04	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2023-09-06	17Q	FIRST EXAMINATION REPORT DESPATCHED	EP
2023-09-20	P01	OPT-OUT OF THE COMPETENCE OF THE UNIFIED PATENT COURT (UPC) REGISTERED	EP
2025-11-11	REG	REFERENCE TO A NATIONAL CODE	EP
2025-11-21	GRAP	DESPATCH OF COMMUNICATION OF INTENTION TO GRANT A PATENT	EP
2025-11-21	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2025-12-17	RIC1	INFORMATION PROVIDED ON IPC CODE ASSIGNED BEFORE GRANT	EP
2025-12-24	INTG	INTENTION TO GRANT ANNOUNCED	EP
2026-06-12	GRAS	GRANT FEE PAID	EP
2026-06-19	GRAA	(EXPECTED) GRANT	EP
2026-06-19	STAA	INFORMATION ON THE STATUS OF AN EP PATENT APPLICATION OR GRANTED EP PATENT	EP
2026-07-22	AK	DESIGNATED CONTRACTING STATES	EP
2026-07-22	REG	REFERENCE TO A NATIONAL CODE	EP
2026-07-24	PLBI	OPPOSITION FILED	EP
2026-07-29	REG	REFERENCE TO A NATIONAL CODE	EP
2026-08-06	REG	REFERENCE TO A NATIONAL CODE	EP
2026-08-12	REG	REFERENCE TO A NATIONAL CODE	EP
2026-08-21	PLBI	OPPOSITION FILED	EP
2026-08-26	26	OPPOSITION FILED	EP
2026-08-26	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-03	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-07	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-17	REG	REFERENCE TO A NATIONAL CODE	EP
2026-09-23	26	OPPOSITION FILED	EP
2026-09-30	REG	REFERENCE TO A NATIONAL CODE	EP
2026-10-19	REG	REFERENCE TO A NATIONAL CODE	EP

Patent & Non-Patent Citations

Cited documents and prior art referenced in search and examination reports.

115 Citations

Cited Patent Documents

WO2008156712

Espacenet

WO2017106656

Espacenet

WO2017210624

Espacenet

US2016022814

Espacenet

WO2016137850

Espacenet

WO2014100079

Espacenet

US4816567

Espacenet

WO2014165422

Espacenet

US7521051

Espacenet

US8008449

Espacenet

US8354509

Espacenet

WO2012135408

Espacenet

US6329511

Espacenet

WO2016176504

Espacenet

WO2017132508

Espacenet

Non-Patent Scientific Literature (NPL)

- SHARPE ET AL.: "The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection", NATURE IMMUNOLOGY, vol. 8, 2007, pages 239 - 245

- DONG ET AL., NATMED, vol. 8, no. 8, 2002, pages 793 - 800

- YANG ET AL., INVEST OPHTHALMOL VIS SCI, vol. 49, 2008, pages 2518 - 2525

- GHEBEH ET AL., NEOPLASIA, vol. 8, 2006, pages 190 - 198

- HAMANISHI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 3360 - 3365

- THOMPSON ET AL., CANCER, vol. 5, 2006, pages 206 - 211

- NOMI ET AL., CLIN. CANCER RESEARCH, vol. 13, 2007, pages 2151 - 2157

- OHIGASHI ET AL., CLIN. CANCER RESEARCH, vol. 11, 2005, pages 2947 - 2953

- INMAN ET AL., CANCER, vol. 109, 2007, pages 1499 - 1505

- SHIMAUCHI ET AL., INT. J. CANCER, vol. 121, 2007, pages 2585 - 2590

- GAO ET AL., CLIN. CANCER RESEARCH, vol. 15, 2009, pages 971 - 979

- NAKANISHI J, CANCER IMMUNOL IMMUNOTHER., vol. 56, 2007, pages 1173 - 1182

- HINO ET AL., CANCER, vol. 00, 2010, pages 1 - 9

- GHEBEH ET AL., BMC CANCER, vol. 8, 2008, pages 5714 - 15

- AHMADZADEH ET AL., BLOOD, vol. 114, 2009, pages 1537 - 1544

- THOMPSON ET AL., CLINICAL CANCER RESEARCH, vol. 15, 2007, pages 1757 - 1761

- BRAHMER ET AL., N ENGL JMED, vol. 366, 2012, pages 2455 - 65

- GARON ET AL., N ENGLJMED, vol. 372, 2015, pages 2018 - 28

- WOLCHOK ET AL., N ENGL J MED, vol. 369, 2013, pages 122 - 33

- ROBERT ET AL., LANCET, vol. 384, 2014, pages 1109 - 17

- ROBERT ET AL., N ENGLJ MED, vol. 372, 2015, pages 2521 - 30

- TOPALIAN ET AL., N ENGL J MED, vol. 366, 2012, pages 2443 - 54

- TOPALIAN ET AL., J CLIN ONCOL, vol. 32, 2014, pages 1020 - 30

- ELASSAISS-SCHAAP ET AL., CPT PHARMACOMETRICS SYST PHARMACOL, vol. 6, 2017, pages 21 - 28

- CASTELLINO, MEDSCAPE MEDICAL NEWS, 2017

- W. A. WEBER, J. NUCL. MED, vol. 50, 2009, pages 1 - 10

- CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883

- CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628

- KABAT: "Adv. Prot. Chem", vol. 32, 1978, pages: 1 - 75

- KABAT ET AL.: "J. Biol. Chem.", vol. 252, 1977, pages: 6609 - 6616

- CHOTHIA ET AL., J MOL. BIOL., vol. 196, 1987, pages 901 - 917

- CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917

- AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948

- WATSON ET AL.: "Molecular Biology of the Gene", 1987, BENJAMIN/CUMMINGS PUB. CO, pages: 224

- CHEN, B.J ET AL., CLIN CANCER RES, vol. 19, 2013, pages 3462 - 3473

- KOHLER ET AL., NATURE, vol. 256, 1975, pages 495

- MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597

- PRESTA, J. ALLERGY CLIN. IMMUNOL, vol. 116, 2005, pages 731

- THOMPSON ET AL., PNAS, vol. 101, no. 49, 2004, pages 17174 - 17179

- THOMPSON ET AL., CANCER RES., vol. 66, 2006, pages 3381 - 3385

- GADIOT ET AL., CANCER, vol. 117, 2011, pages 2192 - 2201

- TAUBE ET AL., SCI TRANSL MED, vol. 4, 2012, pages 127 - 37

- TOPLIAN ET AL., NEW ENG. J MED, vol. 366, no. 26, 2012, pages 2443 - 2454

- EISENHAUER, E.A ET AL., EUR. J. CANCER, vol. 45, 2009, pages 228 - 247

- WHO, DRUG INFORMATION, vol. 27, no. 2, 2013, pages 161 - 162

- AGNEW, CHEM, INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186

- VAUGHAN ET AL., NATURE BIOTECHNOL, vol. 14, 1996, pages 309 - 314

- LE DOUSSAL ET AL., J. IMMUNOL., vol. 146, 1991, pages 169 - 175

- WU: "Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases", vol. 217, 1993, ACADEMIC PRESS

- BAERT ET AL., NEW ENGL. J. MED, vol. 348, 2003, pages 601 - 608

- MILGROM ET AL., NEW ENGL. J. MED, vol. 341, 1999, pages 1966 - 1973

- SLAMON ET AL., NEW ENGL. J. MED, vol. 344, 2001, pages 783 - 792

- BENIAMINOVITZ ET AL., NEW ENGL. J. MED, vol. 343, 2000, pages 1594 - 1602

- GHOSH ET AL., NEW ENGL. J. MED., vol. 348, 2003, pages 24 - 32

- SHAPIRO: "hysicians' Desk Reference", 2003, MEDICAL ECONOMICS COMPANY, article "Molecular Probesy"

- SAMBROOKFRITSCHMANIATIS: "Molecular Cloning, A Laboratory Manual", 1982, COLD SPRING HARBOR LABORATORY PRESS

- SAMBROOKRUSSELL: "Current Protocols in Molecular Biology", vol. 1-4, 2001, COLD SPRING HARBOR LABORATORY PRESS, pages: 384 - 391

- CARPENTER ET AL., J. IMMUNOL, vol. 165, 2000, pages 6205

- TANG ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 27371 - 27378

- HARLOWLANE: "Antibodies A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS, pages: 139 - 243

- HE ET AL., J. IMMUNOL, vol. 160, 1998, pages 1029

- BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684

- FOOTEWINTER, J. MOL. BIOL., vol. 224, 1992, pages 487 - 499

- BARBAS, NATURE MEDICINE, vol. 1, 1995, pages 837 - 839

- MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156

- WRIGHT ET AL., IMMUNITY, vol. 13, 2000, pages 233 - 242

- KAY ET AL.: "Phage Display of Peptides and Proteins: A Laboratory Manual", 1996, ACADEMIC PRESS

- DE BRUIN ET AL., NATURE BIOTECHNOL., vol. 17, 1999, pages 397 - 399

- MEYAARD ET AL., IMMUNITY, vol. 7, 1997, pages 283 - 290

- KAITHAMANA ET AL., J. IMMUNOL., vol. 162, 1999, pages 2804 - 2811

- GIBELLINI, J. IMMUNOL., vol. 160, 1998, pages 3891 - 3898

- EVERTS ET AL., J. IMMUNOL., vol. 168, 2002, pages 883 - 889

- OWENS ET AL.: "Flow Cytometry Principles for Clinical Laboratory Practice", 1994, JOHN WILEY AND SONS

- VON HEIJNE, NUCLEIC ACIDS RES., vol. 14, 1986, pages 4683 - 4690

- MENNE ET AL., BIOINFORMATICS APPLICATIONS NOTE, vol. 16, 2000, pages 741 - 742

- WREN ET AL., COMPUT. METHODS PROGRAMS BIOMED, vol. 68, 2002, pages 177 - 181

- VON HEIJNE, EUR. J. BIOCHEM, vol. 133, 1983, pages 17 - 21

- TSUMURA R ET AL: "The dissociation constant rate of ADC would be an important factor for antitumor activity in vivo", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 77, no. 13, Supplement 1, 1 July 2017 (2017-07-01), XP002804391, ISSN: 1538-7445, DOI: 10.1158/1538-7445.AM2017-4602

- MAYAWALA KAPIL ET AL: "Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 57, 15 September 2017 (2017-09-15), US, pages S143 - S145, XP055880099, ISSN: 0091-2700, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcph.1001> DOI: 10.1002/jcph.1001

- CASTELLINO ALEXANDER M: "Pembrolizumab Flat Dosing Wastes Nearly $1 Billion Annually", MEDSCAPE MEDICAL NEWS > CONFERENCE NEWS > AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2017 ANNUAL MEETING, 26 June 2017 (2017-06-26), XP055857639, Retrieved from the Internet <URL:https://www.medscape.com/viewarticle/882104> [retrieved on 20211103]

- GOLDSTEIN DANIEL A. ET AL: "A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.", JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15_suppl, 20 May 2017 (2017-05-20), US, pages 9013 - 9013, XP055857632, ISSN: 0732-183X, Retrieved from the Internet <URL:http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.9013> DOI: 10.1200/JCO.2017.35.15_suppl.9013

- ZHAO ET AL: "Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types", INTERNET CITATION, 1 July 2017 (2017-07-01), XP002789768, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/77/13_Supplement/CT101>

- ELASSAISS-SCHAAP J ET AL: "Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial : Modeling of the PK/PD of Pembro in KEYNOTE-001", vol. 6, no. 1, 8 November 2016 (2016-11-08), pages 21 - 28, XP055857680, ISSN: 2163-8306, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpsp4.12132> DOI: 10.1002/psp4.12132

- WALKER SCOTT ET AL: "Dosing and Timing of Immuno-Oncology Drugs", no. 25, 1 November 2019 (2019-11-01), XP055857664, ISSN: 2369-7385, Retrieved from the Internet <URL:https://www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf>

- LALA MALLIKA ET AL: "A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM NL, vol. 131, 15 April 2020 (2020-04-15), pages 68 - 75, XP086150533, ISSN: 0959-8049, [retrieved on 20200415], DOI: 10.1016/J.EJCA.2020.02.016

- FDA: "HIGHLIGHTS OF PRESCRIBING INFORMATION KEYTRUDA (pembrolizumab), reference id 4187409", HTTPS://WWW.ACCESSDATA.FDA.GOV, FDA, 1 November 2017 (2017-11-01), pages 1 - 45, XP093420054, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s031lbl.pdf>

- KOYFMAN SHLOMO A., LEE JENNY HJ, MORTIER LAURENT, BRATLAND ÅSE, LUNA-ROMERO NOEL ESAUL, CHIPMAN MITCHELL, DZIENIS MARCIN, KLOCHIKH: "Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).", 2025 ASCO ANNUAL MEETING, AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO), vol. 43, 1 June 2025 (2025-06-01), US, pages 1 - 3, XP093420059, DOI: 10.1200/jco.2025.43.16_suppl.6000

- MERCK: "Merck Provides Further Update on Three Multiple Myeloma Studies Evaluating KEYTRUDA (pembrolizumab) in Combination with Pomalidomide or Lenalidomide", HTTPS://WWW.MERCK.COM, MERCK & CO., INC., 5 July 2017 (2017-07-05), pages 1 - 11, XP093420062, Retrieved from the Internet <URL:https://www.merck.com/news/merck-provides-further-update-on-three-multiple-myeloma-studies-evaluating-keytruda-pembrolizumab-in-combination-with-pomalidomide-or-lenalidomide/>

- TOMOKO FRESHWATER;ANNA KONDIC;MALIDI AHAMADI;CLAIREH. LI;RIK DE GREEF;DINESH DE ALWIS;JULIEA. STONE: "Evaluation of dosing strategy for pembrolizumab for oncology indications", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 5, no. 1, 16 May 2017 (2017-05-16), UK, pages 1 - 9, XP021245121, DOI: 10.1186/s40425-017-0242-5

- D5 - Applicant’s response dated May 06, 2024 filed during examination proceedings of the opposed patent

- SHEINER LEWIS: "The Population Approach to Pharmacokinetic Data Analysis: Rationale and Standard Data Analysis Methods", DRUG METABOLISM REVIEWS, INFORMA HEALTHCARE, USA, vol. 15, no. 1, 22 January 1984 (1984-01-22), USA , pages 153 - 171, XP009568016, ISSN: 1097-9883, DOI: 10.3109/03602538409015063

- AHAMADI M, FRESHWATER T, PROHN M, LI CH, DE ALWIS DP, DE GREEF R, ELASSAISS-SCHAAP J, KONDIC A, STONE JA: "Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors", CPT: PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, vol. 6, no. 1, 1 January 2017 (2017-01-01), pages 49 - 57, XP093420070, ISSN: 2163-8306, DOI: 10.1002/psp4.12139

- WANG W, HALLOW KM, JAMES DA: "A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R", CPT: PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, vol. 5, no. 1, 1 January 2016 (2016-01-01), pages 3 - 10, XP093420072, ISSN: 2163-8306, DOI: 10.1002/psp4.12052

- ANONYMOUS XIAOCHEN, IVATURI VIJAY, GOPALAKRISHNAN MATHANGI, SHEN JUN, FENG YAN, STATKEVICH PAUL, RICHARDS ERIC, RASHFORD MICHELLE,: "Abstract CT101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types", CANCER RESEARCH (CHICAGO, ILL.), AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR), vol. 77, no. 13_Supplement, 1 July 2017 (2017-07-01), pages 1 - 4, XP093420076, ISSN: 0008-5472, DOI: 10.1158/1538-7445.am2017-ct101

- CHATTERJEE M., TURNER D.C., FELIP E., LENA H., CAPPUZZO F., HORN L., GARON E.B., HUI R., ARKENAU H.-T., GUBENS M.A., HELLMANN M.D.: "Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer", ANNALS OF ONCOLOGY, vol. 27, no. 7, 1 July 2016 (2016-07-01), pages 1291 - 1298, XP093420080, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw174

- LALA MALLIKA; LI TOMMY RUOSI; DE ALWIS DINESH P.; SINHA VIKRAM; MAYAWALA KAPIL; YAMAMOTO NOBORU; SIU LILLIAN L.; CHARTASH ELLIOT; : "A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation", EUROPEAN JOURNAL OF CANCER, vol. 131, 15 April 2020 (2020-04-15), ES, pages 68 - 75, XP086150533, ISSN: 0959-8049, DOI: 10.1016/j.ejca.2020.02.016

- RECK MARTIN, RODRÍGUEZ-ABREU DELVYS, ROBINSON ANDREW G., HUI RINA, CSŐSZI TIBOR, FÜLÖP ANDREA, GOTTFRIED MAYA, PELED NIR, TAFRESHI: "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 375, no. 19, 10 November 2016 (2016-11-10), US, pages 1823 - 1833, XP093013864, DOI: 10.1056/NEJMoa1606774

- ZHAO X ET AL: "Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.", ANNALS OF ONCOLOGY, vol. 28, no. 8, 1 August 2017 (2017-08-01), GB , pages 2002 - 2008, XP002789767, ISSN: 1569-8041, DOI: 10.1093/annonc/mdx235

- D17 - Communication pursuant to Article 94(3) EPC dated 7 August 2025

- LEMERY STEVEN J: "Review Memo", 28 April 2020 (2020-04-28), XP093301464, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s59-64%2C69%2C76-83SumR.pdf> * the whole document *

Worldwide Patent Family

Related applications and patents in the same INPADOC worldwide family.

47 Family Members

Country	Publication Number	Kind	Publication Date	Action
EP	EP3752180A2	A2	2020-12-23	Espacenet
EP	EP3752180A4	A4	2021-12-15	Espacenet
EP	EP3752180B1	B1	2026-07-22	Espacenet
AU	AU2019220495A1	A1	2020-08-13	Espacenet
AU	AU2019220495B2	B2	2025-11-13	Espacenet
AU	AU2019222517A1	A1	2020-08-13	Espacenet
AU	AU2023208115A1	A1	2024-01-18	Espacenet
AU	AU2026201041A1	A1	2026-03-05	Espacenet
BR	BR112020015915A2	A2	2020-12-15	Espacenet
BR	BR112020015915A8	A8	2023-01-31	Espacenet
BR	BR112020016331A2	A2	2020-12-15	Espacenet
BR	BR112020016331A8	A8	2023-02-07	Espacenet
CA	CA3090995A1	A1	2019-08-22	Espacenet
CA	CA3090996A1	A1	2019-08-22	Espacenet
CA	CA3307689A1	A1	2026-05-13	Espacenet
CL	CL2020002075A1	A1	2020-10-23	Espacenet
CN	CN111712255A	A	2020-09-25	Espacenet
CN	CN111727056A	A	2020-09-29	Espacenet
CN	CN119792515A	A	2025-04-11	Espacenet
CN	CN120919306A	A	2025-11-11	Espacenet
DK	DK3752180T3	T3	2026-09-07	Espacenet
EP	EP3752193A1	A1	2020-12-23	Espacenet
EP	EP3752193A4	A4	2022-02-23	Espacenet
FI	FI3752180T3	T3	2026-09-17	Espacenet
IL	IL276303A	A	2020-09-30	Espacenet
JP	JP2021513540A	A	2021-05-27	Espacenet
JP	JP2021513541A	A	2021-05-27	Espacenet
JP	JP2024038250A	A	2024-03-19	Espacenet
JP	JP2024038251A	A	2024-03-19	Espacenet
KR	KR20200119844A	A	2020-10-20	Espacenet
KR	KR20200119845A	A	2020-10-20	Espacenet
MA	MA51844A	A	2021-05-19	Espacenet
MA	MA52789A	A	2021-04-14	Espacenet
MA	MA52789B1	B1	2026-09-30	Espacenet
MX	MX2020008445A	A	2020-09-28	Espacenet
MX	MX2020008446A	A	2020-09-28	Espacenet
MX	MX2024013016A	A	2024-11-08	Espacenet
RU	RU2020129075A	A	2022-03-14	Espacenet
RU	RU2020129827A	A	2022-03-14	Espacenet
SG	SG11202007590TA	A	2020-09-29	Espacenet
US	US2021047408A1	A1	2021-02-18	Espacenet
US	US12358984B2	B2	2025-07-15	Espacenet
US	US2021047409A1	A1	2021-02-18	Espacenet
US	US20240026003A1	A1	2024-01-25	Espacenet
WO	WO2019160751A2	A2	2019-08-22	Espacenet
WO	WO2019160751A3	A3	2020-09-10	Espacenet
WO	WO2019160755A1	A1	2019-08-22	Espacenet

Official File Inspection EPC Art. 128 Public Dossier

Complete European Patent Register Dossier (148 Total Documents)

The full inspection file for Application EP19754909 contains 148 total documents, including all notices of opposition, proprietor counter-statements, examination communications, third-party observations, and procedural forms. Below are all major recorded procedural filings and publication specifications.

Open 148-Doc Register Dossier

Recorded Filings & Patent Specifications

Official publication specifications, opposition filings, proprietor replies, and procedural submissions.

81 Filings Listed

European Patent Specification - Granted Patent (B1)

Publication Specification

Date: 2026-07-22 Procedure: Grant EP3752180B1

View / Download PDF

Official European Patent Register Full Dossier

Publication Specification

Date: 2026-07-22 Procedure: All Proceedings (Examination & Opposition) EP19754909

View / Download PDF

European Patent Application without Search Report (A2)

Publication Specification

Date: 2019-08-22 Procedure: Publication EP3752180A2

View / Download PDF

Opposition filed

Dossier Filing

Date: 2026-08-21 Procedure: Opposition 0009260

Inspect on Register

Opposition filed

Dossier Filing

Date: 2026-07-24 Procedure: Opposition 0009260

Inspect on Register

Change - divisional application(s)

Dossier Filing

Date: 2026-07-17 Procedure: Examination 0008299DANR

Inspect on Register

(Expected) grant

Dossier Filing

Date: 2026-06-19 Procedure: Grant 0009210

Inspect on Register

New entry: Decision on request for further processing

Dossier Filing

Date: 2026-06-16 Procedure: Examination EPIDOSNRFP4

Inspect on Register

New entry: Payment of fee for grant

Dossier Filing

Date: 2026-06-12 Procedure: Grant EPIDOSNIGR3

Inspect on Register

New entry: Payment of fee for publishing/printing

Dossier Filing

Date: 2026-06-12 Procedure: Examination EPIDOSNIGR5

Inspect on Register

New entry: Receipt of the translation of the claim(s)

Dossier Filing

Date: 2026-06-12 Procedure: Examination EPIDOSNIGR7

Inspect on Register

New entry: Receipt of request for further processing

Dossier Filing

Date: 2026-06-12 Procedure: Examination EPIDOSNRFP1

Inspect on Register

METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES

Patent Abstract / Summary

IPC Classifications

Priority Claims

Designated Contracting States (38 EPC States)

Parties & Representation

Applicants

Inventors (3)

Representatives / Agents

Key Procedural Dates

Patent Oppositions

Abbott Production Operations AG

Wuesthoff & Wuesthoff Patentanwälte und Rechtsanwalt PartG mbB

Abbott Production Operations AG

Legal Status & Event History

Patent & Non-Patent Citations

Cited Patent Documents

Non-Patent Scientific Literature (NPL)

Worldwide Patent Family

Complete European Patent Register Dossier (148 Total Documents)

Recorded Filings & Patent Specifications

European Patent Specification - Granted Patent (B1)

Official European Patent Register Full Dossier

European Patent Application without Search Report (A2)

Opposition filed

Opposition filed

Change - divisional application(s)

(Expected) grant

New entry: Decision on request for further processing

New entry: Payment of fee for grant

New entry: Payment of fee for publishing/printing

New entry: Receipt of the translation of the claim(s)

New entry: Receipt of request for further processing

New entry: Fee payment for request for further processing

Request for further processing

New entry: Application deemed to be withdrawn: despatch of communication + time limit

Application deemed to be withdrawn

New entry: Renewal fee paid

Renewal fee payment

New entry: Communication of intention to grant a patent

Intention to grant the patent

Change - classification

New entry: Reply to examination report

New entry: Despatch of examination report + time limit

Communication from the examining division

Change - representative

New entry: Renewal fee paid

Renewal fee payment

New entry: Decision on request for further processing

New entry: Reply to examination report

New entry: Receipt of request for further processing

New entry: Fee payment for request for further processing

Request for further processing

New entry: Application deemed to be withdrawn: despatch of communication + time limit

New entry: Renewal fee paid

Renewal fee payment

Change: Despatch of examination report + time limit

New entry: Despatch of examination report + time limit

First examination report

Communication from the examining division

New entry: Renewal fee paid

Renewal fee payment

New entry: Decision on request for further processing

New entry: Receipt of request for further processing

New entry: Fee payment for request for further processing

Amendment by applicant

Change - applicant

Amendments

Request for further processing

Change - representative

New entry: Application deemed to be withdrawn: despatch of communication + time limit

New entry: Renewal fee paid

Renewal fee payment

Supplementary search report

Change - classification

Change: Validation states

New entry: Observations by third parties

New entry: Fee payment for extension state

New entry: Fee payment for validation state

Request for examination filed